To our readers:

With deep regrets, we inform our Readers that the article Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer (DOI: <http://dx.doi.org/10.4081/oncol.2014.236>), which has been published Ahead of Print in the first issue of Oncology Reviews (2014), contains verbatim text plagiarized from another paper.^[@ref1]^

The manuscript must be considered as retracted.

On behalf of the Editorial Board of *Oncology Reviews*, I apologize to the Author of the manuscript whose text was plagiarized by Y. Abubakr and Y. Albushra that this was not picked up in the peer review process. I also apologize to the affected journal for the violation of copyright due to plagiarism.

*Oncology Reviews* is uncompromising in its commitment to scientific integrity. When credible evidence of misconduct is brought to our attention, our commitment to the scientific record and to our readership requires immediate notification.

*Oncology Reviews* is increasingly employing sophisticated software to detect plagiarism. Other journals use similar tools. Authors should be aware that most journals routinely employ plagiarism detection software, and that any plagiarism is likely to be detected.
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